Genetic variations in SLC3A2/CD98 gene as prognosis predictors in non-small cell lung cancer

Molecular Carcinogenesis

Volumn 54, Issue S1, 2015, Pages E52-E60

  Guo, Xu ^a   Li, Hongwei ^a   Fei, Fei ^a   Liu, Boya ^b   Li, Xiaofei ^b   Yang, Hushan ^c   Chen, Zhinan ^a   Xing, Jinliang ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

CD98; NSCLC; Prognosis; Single nucleotide polymorphism

Indexed keywords

ADULT; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CD98 GENE; CONTROLLED STUDY; DNA FLANKING REGION; FEMALE; GENE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; SLC3A2 GENE; AGED; CHINA; ETHNOLOGY; GENETICS; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

CD98 ANTIGEN; SLC3A2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ANTIGENS, CD98 HEAVY CHAIN; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS;

EID: 84931058590     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22167     Document Type: Article

References (35)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90.
2. Lee CB, Stinchcombe TE, Rosenman JG, Socinski MA. Therapeutic advances in local-regional therapy for stage III non-small-cell lung cancer: Evolving role of dose-escalated conformal (3-dimensional) radiation therapy. Clin Lung Cancer 2006; 8:195-202.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
4. Haynes BF, Hemler ME, Mann DL, et al. Characterization of a monoclonal antibody (4F2) that binds to human monocytes and to a subset of activated lymphocytes. J Immunol 1981; 126:1409-1414.
5. Cho JY, Kim AR, Joo HG, et al. Cynaropicrin, a sesquiterpene lactone, as a new strong regulator of CD29 and CD98 functions. Biochem Biophys Res Commun 2004; 313:954-961.
6. Reynolds B, Laynes R, Ogmundsdottir MH, Boyd CA, Goberdhan DC. Amino acid transporters and nutrient-sensing mechanisms: New targets for treating insulin-linked disorders? Biochem Soc Trans 2007; 35:1215-1217.
7. Kaira K, Oriuchi N, Imai H, et al. Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in surgically resectable stage III non-small cell lung cancer. Exp Ther Med 2010; 1:799-808.
8. Rintoul RC, Buttery RC, Mackinnon AC, et al. Cross-linking CD98 promotes integrin-like signaling and anchorage-independent growth. Mol Biol Cell 2002; 13:2841-2852.
9. Prager GW, Poettler M, Schmidinger M, et al. CD98hc (SLC3A2), a novel marker in renal cell cancer. Eur J Clin Invest 2009; 39:304-310.
10. Salter DM, Krajewski AS, Sheehan T, Turner G, Cuthbert RJ, McLean A. Prognostic significance of activation and differentiation antigen expression in B-cell non-Hodgkin's lymphoma. J Pathol 1989; 159:211-220.
11. Kaira K, Ohde Y, Endo M, et al. Expression of 4F2hc (CD98) in pulmonary neuroendocrine tumors. Oncol Rep 2011; 26:931-937.
12. Kaira K, Takahashi T, Abe M, et al. CD98 expression is associated with the grade of malignancy in thymic epithelial tumors. Oncol Rep 2010; 24:861-867.
13. Kaira K, Oriuchi N, Imai H, et al. Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in early stage squamous cell carcinoma of the lung. Cancer Sci 2009; 100:248-254.
14. Kaira K, Oriuchi N, Imai H, et al. Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinoma. Lung Cancer 2009; 66:120-126.
15. Di Paolo A, Danesi R, Del Tacca M. Pharmacogenetics of neoplastic diseases: New trends. Pharmacol Res 2004; 49:331-342.
16. Zhang M, Hu Z, Huang J, et al. A 3′-untranslated region polymorphism in IGF1 predicts survival of non-small cell lung cancer in a Chinese population. Clin Cancer Res 2010; 16:1236-1244.
17. Yin J, Lu C, Gu J, et al. Common genetic variants in cell cycle pathway are associated with survival in stage III-IV non-small-cell lung cancer. Carcinogenesis 2011; 32:1867-1871.
18. Bi N, Yang M, Zhang L, et al. Cyclooxygenase-2 genetic variants are associated with survival in unresectable locally advanced non-small cell lung cancer. Clin Cancer Res 2010; 16:2383-2390.
19. Xu Z, Taylor JA. SNPinfo: Integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic Acids Res 2009; 37(Web Server issue):W600-W605.
20. McShane LM, Altman DG, Sauerbrei W, et al. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 2005; 93:387-391.
21. Holte H, Davies CD, Kvaloy S, et al. The activation-associated antigen 4F2 predicts patient survival in low-grade B-cell lymphomas. Int J Cancer 1987; 39:590-594.
22. Holte H, de Lange Daviesx C, Beiske K, et al. Ki67 and 4F2 antigen expression as well as DNA synthesis predict survival at relapse/tumour progression in low-grade B-cell lymphoma. Int J Cancer 1989; 44:975-980.
23. Furuya M, Horiguchi J, Nakajima H, Kanai Y, Oyama T. Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis. Cancer Sci 2012; 103:382-389.
24. Feral CC, Nishiya N, Fenczik CA, Stuhlmann H, Slepak M, Ginsberg MH. CD98hc (SLC3A2) mediates integrin signaling. Proc Natl Acad Sci USA 2005; 102:355-360.
25. Ohkawa M, Ohno Y, Masuko K, et al. Oncogenicity of L-type amino-acid transporter 1 (LAT1) revealed by targeted gene disruption in chicken DT40 cells: LAT1 is a promising molecular target for human cancer therapy. Biochem Biophys Res Commun 2011; 406:649-655.
26. Chasman DI, Fuchsberger C, Pattaro C, et al. Integration of genome-wide association studies with biological knowledge identifies six novel genes related to kidney function. Hum Mol Genet 2012; 21:5329-5343.
27. Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 1998; 273:23629-23632.
28. Yanagida O, Kanai Y, Chairoungdua A, et al. Human L-type amino acid transporter 1 (LAT1): Characterization of function and expression in tumor cell lines. Biochim Biophys Acta 2001; 1514:291-302.
29. Meier C, Ristic Z, Klauser S, Verrey F. Activation of system L-heterodimeric amino acid exchangers by intracellular substrates. EMBO J 2002; 21:580-589.
30. Huck L, Pontier SM, Zuo DM, Muller WJ. beta1-integrin is dispensable for the induction of ErbB2 mammary tumors but plays a critical role in the metastatic phase of tumor progression. Proc Natl Acad Sci USA 2010; 107:15559-15564.
31. Lahlou H, Sanguin-Gendreau V, Zuo D, et al. Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression. Proc Natl Acad Sci USA 2007; 104:20302-20307.
32. Desgrosellier JS, Cheresh DA. Integrins in cancer: Biological implications and therapeutic opportunities. Nat Rev Cancer 2010; 10:9-22.
33. Harburger DS, Calderwood DA. Integrin signalling at a glance. J Cell Sci 2009; 122:159-163.
34. Cai S, Bulus N, Fonseca-Siesser PM, et al. CD98 modulates integrin beta1 function in polarized epithelial cells. J Cell Sci 2005; 118:889-899.
35. Fenczik CA, Sethi T, Ramos JW, Hughes PE, Ginsberg MH. Complementation of dominant suppression implicates CD98 in integrin activation. Nature 1997; 390:81-85.